Ensure your Dog enjoys Optimal Health and Longevity! Try a Proprietary Formula for Canine Health based on Ayurveda - the Oldest and Most Holistic, Comprehensive Medical System Available.
If you want to maximize your dog's longevity and eliminate fluctuating weight, molting fur, bad odor, anxiety, aggression, or sluggish behavior, there is proven help available. India's domesticated animals have been reaping the powerful benefits of Ayurveda Medicine for the past 5,000 years!
AyurDog is a natural herbal supplement geared towards optimizing your dog's overall health, appearance, and longevity. It will: Fortify Your Dog's Immune System. Reduce Aggression and Stress. Increase Receptivity to Learning. Remove Parasites and Toxins.
Enhance Your Dog's Coat Luster. Rejuvenate Joints and Muscles. Eliminate Bad Odor. AyurDog is a product of: 5000 years of Ayurvedic wisdom. Modern testing and research. Breakthrough encapsulation technique. Laboratory-controlled potency. Doctor-approved, carefully calibrated formula.
http://www.india-herbs.com/aff/dreddyclinic/ayurdog
Rabu, 07 November 2007
Minggu, 04 November 2007
New Heart Pump Helps Women Awaiting Transplants
(HealthDay News) -- An implantable device that helps the heart pump blood -- and is about the size of a "D" battery, one-quarter the weight of the traditional device -- benefits women as well as men who are waiting for heart transplants.
That's the conclusion of new research that's expected to be presented Sunday at the American Heart Association annual meeting in Orlando, Fla.
"In the past, they were not as beneficial in women as in men, partly because of size," said Dr. Suzanne Steinbaum, director of Women and Heart Disease at Lenox Hill Hospital in New York City. "It didn't match up anatomically."
The new device in question, the HeartMate II, is an implantable left ventricular assist device that helps heart function in people with severe congestive heart failure. The U.S. Food and Drug Administration is currently reviewing an application to approve the pump-like device.
According to background information for the study, women with advanced heart failure tended to be underrepresented in studies of left ventricular assist devices (LVADs). Only 9 percent to 16 percent of participants in trials of the first generation of the device were women.
The new trial included 231 patients with heart failure, 23 percent of whom were women being treated at one of 40 different U.S. heart transplant centers and were awaiting heart transplants.
The device serves as a "bridge" to transplantation.
The average age of the women was 56 (the range was 20 to 69 years). Men in the study averaged 54 years old, with an age range of 17 to 68.
Coronary artery disease was more likely to be the cause of heart failure in men -- 43 percent, compared with 31 percent in women.
The women may have suffered a weakened heart because of pregnancy, cancer chemotherapy, a viral infection or some other unknown cause, the researchers said.
Several study participants regained enough pumping power in the heart to have the device removed and no longer needed a transplant. And they've resumed normal physical activities, said the study authors, who are affiliated with such research centers as the Texas Heart Institute in Houston; the University of Rochester in New York; Johns Hopkins Hospital in Baltimore; Duke University, in Durham, N.C.; and Massachusetts General Hospital, in Boston.
Among the study's other findings:
That's the conclusion of new research that's expected to be presented Sunday at the American Heart Association annual meeting in Orlando, Fla.
"In the past, they were not as beneficial in women as in men, partly because of size," said Dr. Suzanne Steinbaum, director of Women and Heart Disease at Lenox Hill Hospital in New York City. "It didn't match up anatomically."
The new device in question, the HeartMate II, is an implantable left ventricular assist device that helps heart function in people with severe congestive heart failure. The U.S. Food and Drug Administration is currently reviewing an application to approve the pump-like device.
According to background information for the study, women with advanced heart failure tended to be underrepresented in studies of left ventricular assist devices (LVADs). Only 9 percent to 16 percent of participants in trials of the first generation of the device were women.
The new trial included 231 patients with heart failure, 23 percent of whom were women being treated at one of 40 different U.S. heart transplant centers and were awaiting heart transplants.
The device serves as a "bridge" to transplantation.
The average age of the women was 56 (the range was 20 to 69 years). Men in the study averaged 54 years old, with an age range of 17 to 68.
Coronary artery disease was more likely to be the cause of heart failure in men -- 43 percent, compared with 31 percent in women.
The women may have suffered a weakened heart because of pregnancy, cancer chemotherapy, a viral infection or some other unknown cause, the researchers said.
Several study participants regained enough pumping power in the heart to have the device removed and no longer needed a transplant. And they've resumed normal physical activities, said the study authors, who are affiliated with such research centers as the Texas Heart Institute in Houston; the University of Rochester in New York; Johns Hopkins Hospital in Baltimore; Duke University, in Durham, N.C.; and Massachusetts General Hospital, in Boston.
Among the study's other findings:
- Six-month survival was about the same for men and women -- 80.6 percent versus 79.5 percent.
- The study found that 3.3 percent of women and 2.2 percent of men experienced strokes within two days of surgery; 13.6 percent of women and 4 percent of men experienced strokes after that.
- After three months with the device, 76 percent of women and 57 percent of men had increased the distance they could walk in six minutes by more than 200 meters.
- Functionally, it helped women more than men," Steinbaum said.
At the beginning of the study, all patients had Class IV heart failure, meaning they couldn't engage in any physical activity without discomfort. After three months with the device, 84 percent of women and men had only Class I and Class II heart failure symptoms -- no or slight limitations on physical activity. "Eighty-four percent of men and women went from Class IV heart failure -- they couldn't even move without being short of breath -- to Class I and II," Steinbaum said. "It's very exciting."
The trial was funded by Thoratec Corp. of Pleasanton, Calif., which manufactures the device.
One of the study authors is the company's vice president for research and scientific affairs. The other study authors are consultants and serve on a Thoratec advisory board.
More information
The American Heart Association has more on left ventricular assist devices.
Sabtu, 03 November 2007
Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer
(HealthDay News) -- Radiation seed implants, known as brachytherapy, are just as effective for treating prostate cancer in men 60 and younger as they are for older men, a new study finds.
Brachytherapy is a minimally invasive procedure in which small radioactive seeds are placed in the prostate to kill cancer cells. Recovery time after seed implantation is much shorter than surgery, and studies have found brachytherapy to be as effective as surgery.
However, men 60 and younger are often advised to have surgery to remove part or all of the prostate, because many surgeons believe it's more effective long-term, according to background information in a news release about the study.
In this study, researchers analyzed the outcomes of more than 1,700 men with localized prostate cancer treated with brachytherapy at Mount Sinai Medical Center in New York between 1990 and 2005.
They found that men 60 and younger had the same outcomes as older men.
"These results suggest that brachytherapy is extremely effective in curing localized prostate cancer for men aged 60 and younger," lead author Dr. Alice Ho, a radiation oncologist at Memorial Sloan-Kettering Cancer Center in New York, said in a prepared statement.
"When younger men are diagnosed with localized prostate cancer, they should be presented with all viable treatment options, including brachytherapy. Every man with prostate cancer, regardless of his age, should have access to the treatment that is best for his cancer and lifestyle," Ho said.
The findings were expected to be presented Wednesday at the American Society for Therapeutic Radiology and Oncology annual meeting, in Los Angeles.
More information
The American Academy of Family Physicians outlines prostate cancer treatment options.
Brachytherapy is a minimally invasive procedure in which small radioactive seeds are placed in the prostate to kill cancer cells. Recovery time after seed implantation is much shorter than surgery, and studies have found brachytherapy to be as effective as surgery.
However, men 60 and younger are often advised to have surgery to remove part or all of the prostate, because many surgeons believe it's more effective long-term, according to background information in a news release about the study.
In this study, researchers analyzed the outcomes of more than 1,700 men with localized prostate cancer treated with brachytherapy at Mount Sinai Medical Center in New York between 1990 and 2005.
They found that men 60 and younger had the same outcomes as older men.
"These results suggest that brachytherapy is extremely effective in curing localized prostate cancer for men aged 60 and younger," lead author Dr. Alice Ho, a radiation oncologist at Memorial Sloan-Kettering Cancer Center in New York, said in a prepared statement.
"When younger men are diagnosed with localized prostate cancer, they should be presented with all viable treatment options, including brachytherapy. Every man with prostate cancer, regardless of his age, should have access to the treatment that is best for his cancer and lifestyle," Ho said.
The findings were expected to be presented Wednesday at the American Society for Therapeutic Radiology and Oncology annual meeting, in Los Angeles.
More information
The American Academy of Family Physicians outlines prostate cancer treatment options.
Langganan:
Postingan (Atom)
